TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05905172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone capsules
Description: After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo capsules
Description: After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
Study: NCT05874726

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue Sample Collection
Description: Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
Study: NCT05631847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment
Description: It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
Study: NCT05407571

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Significance of Echogenic Amniotic Fluid on Perinatal Outcome
Description: To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
Study: NCT06190522

Intervention type: DIAGNOSTIC_TEST
Intervention: Emergency physician clinical ultrasound
Description: Clinical ultrasound by emergency doctor consisting in obtaining frontal sections of the 2 kidneys and a transverse section of the bladder
Study: NCT05801133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: 200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
Study: NCT06303908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Gymnastics Training
Description: This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
Study: NCT05350410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HALT-AD
Description: HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
Study: NCT06472206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Sessions
Description: Sessions with a Community Health Worker (CHW).
Study: NCT05631847

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endovascular treatment
Description: It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
Study: NCT06357663

Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness practice with Calligraphy
Description: The unique style of Art Meditation where mindfulness (heightened awareness) is achieved by combination of movement and focus on Chinese Tao Calligraphy while chanting a mantra. The practitioners repeatedly trace the lines of Tao calligraphy with fingers and chant the mantra. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age.
Study: NCT05914545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZ-AD004
Description: Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles.
Study: NCT06481098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15275
Description: HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HM15275
Description: HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of HM15275
Description: A sterile, matching solution supplied in pre-filled syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HM15275
Description: A sterile, matching solution supplied in pre-filled syringes.
Study: NCT05862272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix Combination Tablet
Description: A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
Study: NCT05962450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT Cells
Description: the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108\~109cells/m2.

Intervention type: DRUG
Group type: OTHER
Intervention: PD-1
Description: Intravenous infusion, according to the drug instructions.
Study: NCT05631847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis (Alteplase)
Description: Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
Study: NCT06472206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleverCap
Description: The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
Study: NCT04930718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thumb active Exercises
Description: Active específico exercises; Reeducation program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thumb active Exercises
Description: Active específico exercises; Reeducation program
Study: NCT05757388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib + paracetamol
Description: Administers after induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administers after induction of anesthesia.
Study: NCT05845528

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: s-tDCS
Description: - Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: s-tDCS
Description: - Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a- tDCS
Description: - Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: a- tDCS
Description: - Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
Study: NCT05542862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SpikoGen vaccine
Description: Recombinant spike protein based Covid-19 vaccine
Study: NCT04479969

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video Chat
Description: Video chat with health coach using a computer tablet.
Study: NCT06478238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium folinate
Description: Intravenous infusion and/or oral therapy
Study: NCT05955209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin（RC48-ADC）
Description: Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
Study: NCT00851708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600 mg bid orally from day 1 to 7 postoperative
Study: NCT05962450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Intravenous infusion, according to the drug instructions.
Study: NCT05475041

Intervention type: PROCEDURE
Intervention: Major liver resection
Description: Major liver resection (3 or more contiguous segments)

Intervention type: PROCEDURE
Intervention: Technically major liver resection
Description: Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
Study: NCT05952206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiolite: Sirolimus-eluting stent
Description: The angiolite stent (iVascular, Barcelona, Spain) is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design containing a durable biostable coating composed of three layers - acrylate to ensure adhesion to the metal surface, fluoroacrylate that carries the sirolimus, and a top layer of fluoroacrylate to control drug release.
Study: NCT04996043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptide Drink
Description: Testing product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Blank
Study: NCT05962450

Intervention type: DRUG
Group type: OTHER
Intervention: Regorafenib
Description: Oral administration, according to the drug instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral administration, according to the drug instructions.
Study: NCT06026852

Intervention type: DEVICE
Group type: OTHER
Intervention: Prediction of plasma concentration of piperacillin-tazobactam or meropenem
Description: For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Determination of plasma concentration of piperacillin-tazobactam or meropenem
Description: For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.
Study: NCT05873088

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Isometric
Description: Effects of Isometric Exercise in Female Patients With Osteoarthritis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Isotonic Exercise
Description: Effects of Isotonic Exercise in Female Patients With Osteoarthritis
Study: NCT06026852

Intervention type: OTHER
Group type: OTHER
Intervention: Daily short questionnaire
Description: Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.
Study: NCT04528199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLOR (FC303) Injection
Description: Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
Study: NCT05879978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obrixtamig
Description: Obrixtamig

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab
Study: NCT05513963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clairity
Description: Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
Study: NCT05064228

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Rewarding Activity Centered Treatment (m-ReACT)
Description: Participants will utilize m-ReACT for 12-weeks, reporting daily on substance-free activity engagement and enjoyment (EMA). m-ReACT will utilize these EMA reports to generate brief, automated, and personalized feedback about enjoyed categories of substance-free activities as well as make suggestions for increasing engagement in those rewarding, goal-oriented substance-free activities, and provide personalized suggestions of activities of interest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Rewarding Activity Centered Treatment (m-ReACT)
Description: Participants will utilize m-ReACT for 12-weeks, reporting daily on substance-free activity engagement and enjoyment (EMA). m-ReACT will utilize these EMA reports to generate brief, automated, and personalized feedback about enjoyed categories of substance-free activities as well as make suggestions for increasing engagement in those rewarding, goal-oriented substance-free activities, and provide personalized suggestions of activities of interest.
Study: NCT06295302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HWH486
Description: HWH486 capsule was administrated orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo was administrated orally
Study: NCT05374733

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary Physiology assessment
Description: 1. Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~2. Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention.
Study: NCT05610852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvesical Single Port Robotic Partial Prostatectomy
Description: A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity focused ultrasound (HIFU)
Description: Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.
Study: NCT04465396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Injection
Description: Teduglutide was administered using syringe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Injection
Description: Teduglutide was administered using syringe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Injection
Description: Teduglutide was administered using syringe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Injection
Description: Teduglutide was administered using syringe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen injector
Description: Teduglutide was administered using pen injector.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen injector
Description: Teduglutide was administered using pen injector.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen injector
Description: Teduglutide was administered using pen injector.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen injector
Description: Teduglutide was administered using pen injector.
Study: NCT06082648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial magnetic stimulationt
Description: The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
Study: NCT05871450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inclusive events
Description: Inclusive events such as inclusive sport festivals, citizen festivals or working groups at school are organized
Study: NCT05910749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QEEG-Guided sLoreta Neurofeedback Training
Description: The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
Study: NCT05754866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial lung cryobiopsy
Description: Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial lung biopsy
Description: Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.
Study: NCT04894682

Intervention type: BIOLOGICAL
Intervention: Vaccine inoculation against SARS-CoV-2
Description: Inoculation with any type of approved vaccines according to the standard or recommended dose

Intervention type: BIOLOGICAL
Intervention: Vaccine inoculation against SARS-CoV-2
Description: Inoculation with any type of approved vaccines according to the standard or recommended dose
Study: NCT05583981

Intervention type: OTHER
Intervention: Interview
Description: Participate in interview